Adjunctive silymarin supplementation and its effects on disease severity, oxidative stress, and inflammation in patients with Alzheimer's disease.

Autor: Navabi SM; Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran., Elieh-Ali-Komi D; Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany., Afshari D; Department of Neurology, College of Medicine, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran., Goudarzi F; Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran., Mohammadi-Noori E; Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran., Heydari K; Department of Clinical Pharmacy, Faculty of Pharmacy, Islamic, Azad, University of Tehran, Tehran, Iran., Heydarpour F; Social Development and Health Promotion Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran., Kiani A; Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Jazyk: angličtina
Zdroj: Nutritional neuroscience [Nutr Neurosci] 2024 Oct; Vol. 27 (10), pp. 1077-1087. Date of Electronic Publication: 2024 Feb 14.
DOI: 10.1080/1028415X.2023.2301163
Abstrakt: Background: Brain tissue in Alzheimer's patients is exposed to oxidative stress. Silymarin is an adjunct drug that has anti-inflammatory and antioxidant properties.
Objective: This study aimed to evaluate the effect of silymarin on biomarkers of oxidative stress, inflammation, and disease severity in Alzheimer's patients.
Methods: This randomized, single-blind clinical trial study was performed on 33 patients with Alzheimer's disease (AD) whose disease was confirmed by DSM-5 criteria and by brain imaging. Patients in the case group received three 250 mg silymarin capsules daily (each containing 150 mg silymarin), as an adjunctive medication in addition to the routine medication regimen. In the placebo group (control), patients received the same amount of placebo. All patients underwent Mini Mental State Exam (MMSE) and a panel of blood tests including malondialdehyde, neopterin, catalase, paraoxonase-1, total oxidative status, and total antioxidant capacity to reevaluate the changes pre/postintervention at the end of the trimester.
Results: The catalase and MDA serum levels after the adjunctive silymarin treatment decreased significantly (Catalase before silymarin  = 9.29 ± 7.02 vs Catalase after silymarin  = 5.32 ± 2.97, p  = 0.007 and MDA before silymarin  = 4.29 ± 1.90 vs MDA after silymarin  = 1.66 ± 0.84, p  < 0.001) while MMSE increased notably (MMSE before silymarin  = 10.39 ± 6.42 vs MMSE after silymarin  = 13.37 ± 6.81, p  < 0.001).
Conclusion: Silymarin can be effective as an adjunct drug and a powerful antioxidant in reducing oxidative stress and improving the course of AD.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje